Unknown PHASE1 INTERVENTIONAL 3-arm NCT05321732

The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

Sponsor: Daewoong Pharmaceutical Co. LTD.

Conditions Healthy Volunteers

Interventions DWP16001 DWP202010

Updated 5 times since 2022 Last updated: Apr 4, 2022 Started: Dec 10, 2021 Primary completion: Aug 31, 2022 Completion: Aug 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05321732, this PHASE1 trial focuses on Healthy Volunteers and remains ongoing. Sponsored by Daewoong Pharmaceutical Co. LTD., it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Enrolling By Invitation → Unknown Status
May 2022 — Feb 2024 [monthly]

Enrolling By Invitation PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewoong Pharmaceutical Co. LTD.

Data source: Daewoong Pharmaceutical Co. LTD.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea